Covid-19 疫苗：对其有效性和不良反应的深入了解。
Vaccines for Covid-19: An insight on their effectiveness and adverse effects.
机构信息
Department of Medical Lab Technology, The University of Haripur, Khyber Pakhtunkhwa, Pakistan.
Department of Biomedical Sciences, Pak-Austria Fachhochschule Institute of Applied Sciences and Technology, Haripur, Khyber Pakhtunkhwa, Pakistan.
出版信息
J Med Virol. 2022 Aug;94(8):3554-3560. doi: 10.1002/jmv.27810. Epub 2022 May 5.
Abstract
An era of SARS-COVID-19 outbreak with a high contagious percentage around the globe has been the subject of multi-agency research aimed at generating vaccines for active immunization. Scientists across the world are joining hands for advanced tie-ups between medical start-ups and pharmaceutical industries for devices and vaccines development to hinder the progress of this outbreak. Moreover, the questions that need to be answered are how to improve the effectiveness and efficacy of vaccines with reduced side effects and the required doses of vaccines for enhanced surveillance. In this review article, we have discussed the effectiveness and efficacy of different Covid-19 vaccines.
摘要
全球范围内具有高传染性百分比的 SARS-COVID-19 爆发时代是多机构研究的主题，旨在为主动免疫生成疫苗。世界各地的科学家正在为医疗初创企业和制药行业之间的先进合作牵线搭桥，以开发设备和疫苗，以阻止这一爆发的进展。此外，需要回答的问题是如何提高疫苗的有效性和功效，同时减少副作用，并减少所需的疫苗剂量以进行强化监测。在这篇综述文章中，我们讨论了不同 COVID-19 疫苗的有效性和功效。
相似文献
1
Vaccines for Covid-19: An insight on their effectiveness and adverse effects.Covid-19 疫苗：对其有效性和不良反应的深入了解。
J Med Virol. 2022 Aug;94(8):3554-3560. doi: 10.1002/jmv.27810. Epub 2022 May 5.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study.加拿大努纳武特地区非药物干预和疫苗接种对 COVID-19 疫情的影响：加拿大免疫研究网络（CIRN）研究。
BMC Public Health. 2022 May 25;22(1):1042. doi: 10.1186/s12889-022-13432-1.
4
A review of the safety and efficacy of current COVID-19 vaccines.当前 COVID-19 疫苗的安全性和有效性综述。
Front Med. 2022 Feb;16(1):39-55. doi: 10.1007/s11684-021-0893-y. Epub 2022 Feb 3.
5
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.75 岁及以上成年人接种 BNT162b2 新冠疫苗后的安全性监测。
J Korean Med Sci. 2021 Nov 22;36(45):e318. doi: 10.3346/jkms.2021.36.e318.
6
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
7
[Vaccination contre le SARS-CoV-2, le Graal ?].[新冠病毒疫苗接种，是万灵药吗？]
Rev Prat. 2022 May;72(5):517-522.
8
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.在广州，灭活的 SARS-CoV-2 疫苗对 Delta 变异株感染的有效性：一项病例对照的真实世界研究。
Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. doi: 10.1080/22221751.2021.1969291.
9
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗：除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
10
COVID-19: vaccination problems.新型冠状病毒肺炎：疫苗接种问题。
Environ Microbiol. 2021 Jun;23(6):2878-2890. doi: 10.1111/1462-2920.15549. Epub 2021 May 14.
引用本文的文献
1
Visual analysis on ferroptosis and its cross-talk to coronavirus disease 2019 (COVID-19).铁死亡及其与2019冠状病毒病（COVID-19）相互作用的可视化分析
Heliyon. 2024 Sep 7;10(17):e37617. doi: 10.1016/j.heliyon.2024.e37617. eCollection 2024 Sep 15.
2
Study on Preclinical Safety and Toxic Mechanism of Human Umbilical Cord Mesenchymal Stem Cells in F344RG Rats.人脐带间充质干细胞在 F344RG 大鼠体内的临床前安全性及毒性机制研究。
Stem Cell Rev Rep. 2024 Nov;20(8):2236-2252. doi: 10.1007/s12015-024-10780-w. Epub 2024 Sep 7.
3
A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病（COVID-19）疫苗研发的文献计量可视化分析
Vaccines (Basel). 2023 Jan 29;11(2):295. doi: 10.3390/vaccines11020295.
4
Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study.墨西哥人群中新冠疫苗接种后不良反应和过敏反应的患病率及危险因素：一项分析性横断面研究
Vaccines (Basel). 2022 Nov 25;10(12):2012. doi: 10.3390/vaccines10122012.
5
Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?临床心血管急症与 COVID-19 疫苗接种的细胞基础：从梦想变为现实？
Int J Infect Dis. 2022 Nov;124:1-10. doi: 10.1016/j.ijid.2022.08.026. Epub 2022 Sep 6.
6
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.mRNA-1273、BNT162b2 和 Ad26.COV2.S 疫苗接种者对包括德尔塔和奥密克戎在内的关注变异株 SARS-CoV-2 的中和抗体。
J Med Virol. 2022 Dec;94(12):5678-5690. doi: 10.1002/jmv.28032. Epub 2022 Aug 6.
本文引用的文献
1
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
2
mRNA Covid-19 vaccines in pregnancy: A systematic review.mRNA 新冠疫苗在妊娠期的应用：一项系统评价。
PLoS One. 2022 Feb 2;17(2):e0261350. doi: 10.1371/journal.pone.0261350. eCollection 2022.
3
The COVID-19 pandemic in children and young people during 2020-2021: A complex discussion on vaccination.2020 - 2021年儿童和青少年中的新冠疫情：关于疫苗接种的复杂讨论
J Glob Health. 2021 Dec 25;11:01011. doi: 10.7189/jogh.11.01011. eCollection 2021.
4
BNT162b2 Vaccine Booster and Mortality Due to Covid-19.BNT162b2 疫苗加强针与新冠病毒导致的死亡率。
N Engl J Med. 2021 Dec 23;385(26):2413-2420. doi: 10.1056/NEJMoa2115624. Epub 2021 Dec 8.
5
Should children be vaccinated against COVID-19?儿童应该接种 COVID-19 疫苗吗？
Arch Dis Child. 2022 Mar;107(3):e1-e8. doi: 10.1136/archdischild-2021-323040. Epub 2021 Nov 3.
6
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.BNT162b2 mRNA COVID-19 疫苗在妊娠中的有效性。
Nat Med. 2021 Oct;27(10):1693-1695. doi: 10.1038/s41591-021-01490-8. Epub 2021 Sep 7.
7
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
8
Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign.牛津大学-阿斯利康新冠疫苗：需要一场合理且有效的疫苗接种运动。
Public Health. 2021 Jul;196:135-137. doi: 10.1016/j.puhe.2021.05.030. Epub 2021 Jun 2.
9
Mortality Rate and Characteristics of Deaths Following COVID-19 Vaccination.新冠疫苗接种后的死亡率及死亡特征
Front Med (Lausanne). 2021 May 14;8:670370. doi: 10.3389/fmed.2021.670370. eCollection 2021.
10
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
Zotero 插件